시장보고서

상품코드

1790272

포스포라마다이트 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Phosphoramidite Market Size, Share & Trends Analysis Report By Type (DNA Phosphoramidites, RNA Phosphoramidites), By Application (Drug Discovery & Development, Diagnostics Development), By End Use, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

포스포라마다이트 시장 개요

포스포라마다이트 세계 시장 규모는 2024년 11억 5,000만 달러로 평가되었습니다. 2033년에는 22억 7,000만 달러에 달하고, 2025-2033년 8.06%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 시장 성장의 배경에는 올리고뉴클레오티드 생산에서 포스포라마다이트 수요 증가, 유전성 질환 및 감염성 질환의 유병률 증가, 생명공학 및 제약 산업에서 연구개발 활동의 급증으로 인해 포스포라마다이트 수요가 더욱 촉진되고 있습니다.

또한, 노인 인구 증가와 의료비 지출 증가는 향후 몇 년 동안 시장 성장을 가속할 것으로 예측됩니다.

올리고뉴클레오티드 치료에 대한 수요 증가

올리고뉴클레오티드 기반 치료의 채택이 증가하고 있는 것은 포스포라마다이트 산업의 주요 촉진제입니다. 제약사 및 바이오기업들은 항센스 올리고뉴클레오티드(ASO), 저분자 간섭 RNA(siRNA), 메신저 RNA(mRNA) 치료제 개발에 많은 투자를 하고 있으며, 유전성 질환, 감염성 질환, 희귀질환 등 다양한 질환에 대응하고 있습니다. 이러한 치료법은 정확하게 합성된 올리고뉴클레오티드에 의존하며, 포스포아미다이트는 뉴클레오티드 사슬을 구축하는 데 필수적인 화학적 중간체 역할을 합니다. 코로나19 팬데믹 상황에서 mRNA 백신의 성공은 합성 RNA의 치료 가능성을 더욱 검증하고, 올리고 기반 치료법에 대한 연구와 규제 당국의 수용을 가속화했습니다.

ASO와 siRNA는 유전자 발현을 선택적으로 비활성화하거나 조절하는 능력으로 차세대 치료제로 각광받고 있습니다. 이미 여러 ASO 기반 의약품이 규제 당국의 승인을 받았으며, 신경질환, 암, 대사성 질환을 대상으로 하는 강력한 파이프라인이 개발 중입니다. 치료법이 핵산 기반 솔루션으로 전환됨에 따라 고순도, 정제 및 확장 가능한 포스포아미다이트에 대한 수요가 급격히 증가하고 있습니다. 의약품 개발 기업들은 안전성과 효능에 대한 엄격한 규제 기준을 충족하는 일관된 고품질 올리고뉴클레오티드를 필요로 하며, 이에 따라 입증된 합성 능력을 갖춘 신뢰할 수 있는 공급업체에 대한 의존도가 높아지고 있습니다.

또한, mRNA 치료는 백신 외에도 종양학, 심혈관계 질환, 단백질 대체요법 등에도 적용이 검토되고 있습니다. 이러한 발전에 따라 코딩 배열, 변형 캡, 조절 요소 등 보다 복잡하고 특수한 포스포라미다이트가 요구되고 있습니다. 이러한 추세는 안정적인 공급망, 기술 통합, 품질 보증을 보장하기 위해 올리고 제조업체와 제약 혁신가들이 전략적 파트너십을 맺는 것을 촉진하고 있습니다. 핵산 의약품의 세계 파이프라인이 확대되고 임상 검사가 가속화되는 가운데, 포스포라마다이트 산업은 올리고뉴클레오티드 치료의 기반이 되는 존재로서 장기적인 성장이 기대되고 있습니다.

유형 부문 대시보드
세계의 포스포라마다이트 시장 유형 변동 분석
세계의 포스포라마다이트 시장 규모와 동향 분석(유형별, 2021-2033년)
DNA 포스포라마다이트
RNA 포스포라마다이트
표지 포스포라마다이트
수식 포스포라마다이트
기타

제5장 포스포라마다이트 시장 : 용도 비즈니스 분석

용도 부문 대시보드
세계의 포스포라마다이트 시장 용도 변동 분석
세계의 포스포라마다이트 시장 규모와 동향 분석(용도별, 2021-2033년)
Drug Discovery & Development
진단 개발
기타

제6장 포스포라마다이트 시장 : 최종 용도 비즈니스 분석

최종 용도 부문 대시보드
세계의 포스포라마다이트 시장 최종 용도 변동 분석
세계의 포스포라마다이트 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
제약 바이오테크놀러지 기업
학술연구기관
기타

제7장 포스포라마다이트 시장 : 지역별, 추정·동향 분석

지역 대시보드
시장 규모와 예측과 동향 분석, 2018-2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참여 기업
전략 매핑
기업 시장 현황 분석, 2024년
참여 기업 개요
- BOC Sciences
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Glen Research
- LGC Biosearch Technologies
- Biosynth
- BIONEER CORPORATION
- QIAGEN
- PolyOrg, Inc
- Lumiprobe Corporation

LSH 25.08.25

Phosphoramidite Market Summary

The global phosphoramidite market size was estimated at USD 1.15 billion in 2024 and is projected to reach USD 2.27 billion by 2033, growing at a CAGR of 8.06% from 2025 to 2033. The market growth can be attributed to the increasing demand for phosphoramidite in the production of oligonucleotides, the rising prevalence of genetic disorders and infectious diseases has led to a surge in research and development activities in the biotechnology and pharmaceutical industries, which further fuels the demand for phosphoramidite.

Moreover, the growing geriatric population and increasing healthcare expenditure are also expected to drive the market growth in the coming years.

Rising Demand for Oligonucleotide Therapeutics

The increasing adoption of oligonucleotide-based therapeutics is a major growth driver for the phosphoramidite industry. Pharmaceutical and biotechnology companies are investing heavily in the development of antisense oligonucleotides (ASOs), small interfering RNAs (siRNA), and messenger RNA (mRNA) therapies to address a wide range of genetic, infectious, and rare diseases. These therapies rely on precisely synthesized oligonucleotides, with phosphoramidites serving as the essential chemical intermediates for constructing nucleotide chains. The success of mRNA vaccines during the COVID-19 pandemic has further validated the therapeutic potential of synthetic RNA, accelerating research and regulatory acceptance of oligo-based modalities.

ASOs and siRNAs are gaining prominence as next-generation therapeutics due to their ability to selectively silence or modulate gene expression. Multiple ASO-based drugs have already received regulatory approvals, and a robust pipeline is in development targeting neurological disorders, cancers, and metabolic conditions. As the therapeutic landscape shifts towards nucleic acid-based solutions, the demand for high-purity, modified, and scalable phosphoramidites is growing exponentially. Drug developers require consistent and high-quality oligonucleotides that meet stringent regulatory standards for safety and efficacy, thereby increasing reliance on trusted suppliers with proven synthesis capabilities.

In addition, mRNA therapeutics are being explored beyond vaccines, including applications in oncology, cardiovascular diseases, and protein replacement therapies. These advancements demand more complex and specialized phosphoramidites for coding sequences, modified caps, and regulatory elements. This trend is prompting strategic partnerships between oligo manufacturers and pharmaceutical innovators to ensure secure supply chains, technological integration, and quality assurance. With the global pipeline for nucleic acid drugs expanding and clinical trials accelerating, the phosphoramidite industry is well-positioned for long-term growth as a foundational enabler of oligonucleotide therapeutics.

Global Phosphoramidite Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global phosphoramidite market based on type, application, end use, and region.

Type Outlook (Revenue, USD Million, 2021 - 2033)
DNA Phosphoramidites
RNA Phosphoramidites
Labeled Phosphoramidites
Modifier Phosphoramidites
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Drug Discovery & Development
Diagnostics Development
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
- 1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Growth of oligonucleotide therapies
  - 3.2.1.2. Advancements in genomics and personalized medicine
  - 3.2.1.3. Growth in synthetic biology research
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Stringent regulations for oligonucleotide therapies
  - 3.2.2.2. Difficulties in long chain synthesis
3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis

Chapter 4. Phosphoramidite Market: Type Business Analysis

4.1. Type Segment Dashboard
4.2. Global Phosphoramidite Market Type Movement Analysis
4.3. Global Phosphoramidite Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. DNA Phosphoramidites
- 4.4.1. Global DNA Phosphoramidites Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. RNA Phosphoramidites
- 4.5.1. Global RNA Phosphoramidites Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Labeled Phosphoramidites
- 4.6.1. Global Labeled Phosphoramidites Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Modifier Phosphoramidites
- 4.7.1. Global Modifier Phosphoramidites Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
- 4.8.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Phosphoramidite Market: Application Business Analysis

5.1. Application Segment Dashboard
5.2. Global Phosphoramidite Market Application, Movement Analysis
5.3. Global Phosphoramidite Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Drug Discovery & Development
- 5.4.1. Global Drug Discovery & DevelopmentMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Diagnostics Development
- 5.5.1. Global Diagnostics Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Others
- 5.6.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Phosphoramidite Market: End Use Business Analysis

6.1. End Use Segment Dashboard
6.2. Global Phosphoramidite Market End Use Movement Analysis
6.3. Global Phosphoramidite Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
- 6.4.1. Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Academic & Research Institutes
- 6.5.1. Global Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Phosphoramidite Market: Regional Estimates & Trend Analysis

7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3. North America
- 7.3.1. North America Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. U.S. Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Canada Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Competitive Scenario
  - 7.3.4.3. Regulatory Framework
  - 7.3.4.4. Mexico Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Europe
- 7.4.1. Europe Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. UK Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Germany Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. France Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Competitive Scenario
  - 7.4.5.3. Regulatory Framework
  - 7.4.5.4. Italy Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Competitive Scenario
  - 7.4.6.3. Regulatory Framework
  - 7.4.6.4. Spain Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Competitive Scenario
  - 7.4.7.3. Regulatory Framework
  - 7.4.7.4. Denmark Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
  - 7.4.8.1. Key Country Dynamics
  - 7.4.8.2. Competitive Scenario
  - 7.4.8.3. Regulatory Framework
  - 7.4.8.4. Sweden Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key Country Dynamics
  - 7.4.9.2. Competitive Scenario
  - 7.4.9.3. Regulatory Framework
  - 7.4.9.4. Norway Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Japan
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Japan Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. China
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. China Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. India Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Australia
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Australia Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Thailand Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. South Korea
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. South Korea Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Latin America
- 7.6.1. Latin America Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Brazil Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Argentina Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. MEA
- 7.7.1. MEA Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. South Africa Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Saudi Arabia Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
  - 7.7.4.1. Key Country Dynamics
  - 7.7.4.2. Competitive Scenario
  - 7.7.4.3. Regulatory Framework
  - 7.7.4.4. UAE Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key Country Dynamics
  - 7.7.5.2. Competitive Scenario
  - 7.7.5.3. Regulatory Framework
  - 7.7.5.4. Kuwait Phosphoramidite Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Participant's Overview
- 8.4.1. BOC Sciences
  - 8.4.1.1. Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. Thermo Fisher Scientific Inc.
  - 8.4.2.1. Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Merck KGaA
  - 8.4.3.1. Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Glen Research
  - 8.4.4.1. Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. LGC Biosearch Technologies
  - 8.4.5.1. Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. Biosynth
  - 8.4.6.1. Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. BIONEER CORPORATION
  - 8.4.7.1. Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. QIAGEN
  - 8.4.8.1. Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. PolyOrg, Inc
  - 8.4.9.1. Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Lumiprobe Corporation
  - 8.4.10.1. Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives